What is the level of evidence for the recommendation of PCSK9 inhibitors for patients with ASCVD?
The recommendation of PCSK9 inhibitors for patients with ASCVD warrants an level of evidence (LOE) of A, based on the statistically significant results in 2 large randomized control trials (RCTs) showing reductions in ASCVD events in patients with very high risk and low-density lipoprotein cholesterol (LDL-C) levels of 70 mg/dL (1.8 mmol/L) while on maximally tolerated LDL-C lowering therapy.